7 results about "Transcriptional repression" patented technology

The application discloses high-temperature-resistant engineered methanotrophs with high glutamic acid yield, a construction method and application thereof, and belongs to the field of industrial biotechnology. Methylotuvimicrobium buryatense 5GB1 as the host strain, transcriptional inhibition of the SOS response system by LexA protein is removed by knocking out a lexA gene in the genome of the host strain, expression of DNA damage repair related genes in the cell is activated, and high-temperature-resistant engineered methanotrophs MBΔ lexA that can stably grow in a high-temperature environment of 40-45 DEG C are obtained. The strain can still maintain normal growth and metabolism with methane as the sole carbon source under the condition of 40-45 DEG C, and the glutamic acid synthesis capacity of the strain is significantly better than that of the original strain at normal temperature. The high-temperature-resistant engineered methanotrophs MBΔ lexA provide important strain resources for the production of amino acid products by methanotroph cell factories in a high-temperature industrial scene, and are expected to improve the economy and sustainability of methanotrophic bioconversion.

This invention belongs to the field of plant molecular biology and genetic breeding technology, specifically relating to a molecular marker related to the malic acid content of apple fruit and its application. The molecular marker is... MdNAC029 The single nucleotide polymorphism site in the gene promoter region, this site is located MdNAC029 The nucleotide sequence of the gene promoter region, starting from the 2693rd base at the 5' end, corresponds to... MdNAC029 At a position 442 bp upstream of the transcription start codon, the polymorphism is either T or C, with the C / C genotype indicating high malic acid content and the T / T genotype indicating low malic acid content. This invention, through molecular biology experiments, confirms that the T allele is the binding site for the transcriptional repressor MdMYC2, and the C allele eliminates the binding of MdMYC2, thereby relieving transcriptional repression and promoting malic acid accumulation. This provides a new molecular marker for the genetic improvement of apple fruit acidity traits, accelerating the breeding process of superior varieties.

Provided is an epigenetic editor comprising a transcriptional activator-like effector (TALE) domain, at least one epigenetic modification domain, and at least one transcriptional regulatory domain; wherein the TALE domain can be specifically combined with a target nucleotide sequence on an HBV (Hepatitis B Virus) gene and / or a regulatory element of the HBV gene.

This invention discloses the application of the NbMYB159 gene in the positive regulation of the MVA metabolic pathway in Nicotiana benthamiana, belonging to the field of genetic engineering technology. The technical solution includes the application of the NbMYB159 gene in the positive regulation of the MVA metabolic pathway in Nicotiana benthamiana. The nucleotide sequence of the gene is shown in SEQ ID NO: 1. The NbMYB159 gene can enhance the metabolic flux of the MVA pathway by activating the expression of key structural genes in the Nicotiana benthamiana MVA pathway. This invention discovers that NbMYB159 can specifically bind to the promoter regions of NbHMGR and NbHMGS, activating the expression of all genes in the MVA pathway. Transient overexpression of NbMYB159 in Nicotiana benthamiana significantly increases the content of endogenous FPP in Nicotiana benthamiana. Stable overexpression lines significantly increase the content of endogenous FPP in Nicotiana benthamiana without affecting the biomass of Nicotiana benthamiana, while transcriptional repression overexpression lines significantly reduce the content of FPP. This discovery is of great significance for the engineering modification of the Nicotiana benthamiana chassis and can effectively solve the problem of low production efficiency of sesquiterpenes and triterpenes in Nicotiana benthamiana.

This invention relates to a method based on argB A method for constructing a high-arginine-producing genetically engineered strain using mutants, and the application of this genetically engineered strain in the microbial fermentation production of arginine. The genetically engineered strain was obtained by performing the following gene editing on its genome, starting with Corynebacterium glutamicum ATCC 13032; this invention first involves knocking out the gene encoding the arginine biosynthesis repressor protein. argR and last Relieve transcriptional repression; knock out the gene encoding glutamate kinase. proB Blocking the competitive pathway for the synthesis of the byproduct L-proline; knocking out global nitrogen metabolism regulators. amtR To relieve nitrogen metabolism restriction and enhance nitrogen source supply; to knock out the gene encoding the mechanosensitive channel protein. yggB By altering cell membrane permeability and reducing the leakage of byproducts (such as glutamate), it indirectly promotes arginine accumulation; based on the knockout of the original proB, ldh Replace with Ptac- argB *(T94S, I158V, R273K) strains were constructed to reduce lactic acid byproducts while resisting feedback inhibition; finally, the L-arginine exporter gene was overexpressed via plasmid. lysE By combining the above modification strategies, a genetically engineered strain ARG6-Ptac-, which produces high levels of arginine, was constructed. argB * / pXMJ19- lysE This engineered strain exhibits excellent L-arginine production capacity in both shake flask and fermenter scales (10.3 g / L in shake flask and 105.2 g / L in fed-batch fermentation), and its genetic traits are stable, making it suitable for industrial production.

This invention discloses a rutin-containing composition and its applications, belonging to the field of drug development technology. Through molecular docking simulations, animal experiments, and cell experiments, this invention demonstrates that rutin exerts its detoxification effect through a dual mechanism: firstly, it antagonizes the inhibitory effect of α-amatoxins on RNA polymerase II, improving transcriptional repression induced by poisoning; secondly, it alleviates oxidative stress caused by α-amatoxins, reducing MDA content and increasing SOD activity. Rutin significantly improves the survival rate of mice poisoned by α-amatoxins, improves hepatocellular pathological damage, and reduces liver function indicators AST and ALT levels. The optimal dosage is 175 mg / kg, indicating that rutin can be considered a potential therapeutic drug for α-amatoxins poisoning. This invention provides a new treatment option for α-amatoxins poisoning. Rutin is a marketed drug with guaranteed safety and significant advantages for clinical translation.

This invention discloses 4-aminopyrimidine LRH-1 receptor antagonists and their applications, belonging to the field of pharmaceutical technology. This invention provides the application of 4-aminopyrimidine compounds and their derivatives, with the general structural formula shown in Formula (I), in the preparation of antitumor drugs. These compounds, as LRH-1 antagonists, exhibit significant downstream transcriptional repression activity against LRH-1 and have a high affinity for LRH-1 LBD protein, effectively inhibiting the proliferation of growth-dependent LRH-1 tumors such as breast cancer, colon cancer, pancreatic cancer, and prostate cancer cell lines. Therefore, these compounds can be applied to the treatment of diseases related to abnormal LRH-1 expression, including but not limited to the treatment of breast cancer, colon cancer, pancreatic cancer, and prostate cancer.